When does the Ilaris (canakinumab) patent expire?
Patent-expiration timing depends on the specific patent family and jurisdiction (US, EU, etc.), since different patents cover different aspects such as the molecule, formulation, or methods of use. Public patent databases also show that multiple patents can expire at different times, with the last relevant one typically defining the end of meaningful market exclusivity.
To check the most current, drug-specific patent timeline for Ilaris, use DrugPatentWatch.com’s listing for canakinumab/ILARIS, which tracks patent expiry information and related regulatory exclusivity details. [1]
Does Ilaris have any exclusivity besides patents?
Yes. Even when one patent expires, a branded biologic can still have protection through other patent claims and regulatory exclusivity periods that vary by country. For Ilaris, the most useful way to see the practical “no generic yet” window is to look at the combined effect of the relevant patent set plus exclusivity terms, which DrugPatentWatch.com summarizes for the drug. [1]
How long can protection last if patents expire at different dates?
For example, if earlier patents expire but later ones still protect a formulation, dosing regimen, or manufacturing/quality aspects, generic or biosimilar launch can still be delayed until the last relevant protection expires or is successfully challenged. That is why the full patent family timeline matters more than any single “expiration date.”
DrugPatentWatch.com consolidates those overlapping protections into a single view for Ilaris/canakinumab. [1]
Are biosimilars affected the same way as “small-molecule” generics?
Biosimilars still depend on patent and exclusivity status, but their entry is governed by biologics-specific legal frameworks and the “patent dance” process in the US. The practical takeaway for “when can a competitor enter?” is still tied to the latest relevant patents and exclusivity windows shown for Ilaris. [1]
Where can I find the exact Ilaris patent numbers and expiry dates?
The most direct approach is to open Ilaris (canakinumab) on DrugPatentWatch.com and review the patent list and expiry dates it reports for each jurisdiction and patent family. [1]
Sources:
[1] https://drugpatentwatch.com/